/AZTR
AZTR Stock - Azitra, Inc.
Healthcare|BiotechnologyAMEX
$0.29+3.19%
+$0.01 (+3.19%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.32
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AZTR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.29 – $0.30
TARGET (TP)$0.34
STOP LOSS$0.27
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.65
52W High$4.33
52W Low$0.28
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $7.50M | $686,000 | $284,000 | $110,000 |
| Gross Profit | $7.50M | $686,000 | $284,000 | $110,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-10,985,140,000 | $-7,450,546 | $-9,453,604 | $-9,221,454 |
| Net Income | $-8,967,492 | $-11,283,781 | $-10,680,366 | $-8,939,675 |
| Net Margin | -119.6% | -1644.9% | -3760.7% | -8127.0% |
| EPS | $-0.36 | $-7.34 | $-3.98 | $-3.33 |
Company Overview
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
AZTRBeat Rate
80%
Last 5 quarters
Avg Surprise
+17.1%
EPS vs Estimate
Beats / Misses
4/1
Last 12 quarters
Latest EPS
$-0.67
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
No data
Q3 24
+14.9%
$-18.24vs$-21.44
Q4 24
+64.7%
$-1.13vs$-3.20
Q1 25
-23.5%
$-0.63vs$-0.51
Q2 25
No data
Q3 25
+14.3%
$-1.20vs$-1.40
Q4 25
+15.2%
$-0.67vs$-0.79
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 23, 2026 | $-0.37 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.79 | $-0.67 | +15.2% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-1.40 | $-1.20 | +14.3% | ✓ BEAT |
Q2 2025 | May 13, 2025 | — | $-1.53 | — | — |
Q1 2025 | Mar 21, 2025 | $-0.51 | $-0.63 | -23.5% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-3.20 | $-1.13 | +64.7% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-21.44 | $-18.24 | +14.9% | ✓ BEAT |
Q2 2024 | May 9, 2024 | — | $-29.99 | — | — |
Q2 2024 | Apr 29, 2024 | — | $-6.08 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-31.99 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-2.36 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-6.10 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-10.04 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-6.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-4.69 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-5.77 | — | — |
Latest News
Azitra Receives NYSE American Approval Of Compliance Plan, Must Regain Listing Standards By April 1, 2027
➖ NeutralBenzinga•Dec 17, 2025, 09:11 PM
Azitra Prices Private Placement Of 4,687,500 Shares Of Common Stock, Together With Warrants, At Effective Offering Price Of $0.32 For Gross Proceeds ~$1.5M
➖ NeutralBenzinga•Nov 24, 2025, 02:06 PM
Anitra Q3 EPS $(0.67) Beats $(0.78) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 10:17 PM
Azitra shares are trading lower. The company announced that a report suggesting that the company priced a $44 million registed direct offering is false.
📉 NegativeBenzinga•Nov 7, 2025, 03:46 PM
Pharma Company Azitra Shoots Down "False Report" of a $44M Stock Offering
📉 NegativeBenzinga•Nov 7, 2025, 11:06 AM
Azitra denies report of $44 million direct offering, stock drops
📉 NegativeSeeking Alpha•Nov 7, 2025, 11:05 AM
Azitra shares are trading higher after the company announced preclinical progress for its ATR-01 program.
📈 PositiveBenzinga•Oct 20, 2025, 01:09 PM
Azitra To Present Preclinical Progress For ATR-01 Program, Targeting Treatment Of Ichthyosis Vulgaris At BIO-Europe Conference
📈 PositiveBenzinga•Oct 20, 2025, 12:10 PM
Azitra Receives Non-Compliance Letter From NYSE American
📉 NegativeBenzinga•Oct 3, 2025, 08:46 PM
Azitra shares are trading higher after the company announced the dosing of its first patient in its Phase 1/2 trial of ATR04-48.
📈 PositiveBenzinga•Aug 27, 2025, 12:15 PM
Azitra Doses First Patient In Phase 1/2 Trial Of ATR04-484 For EGFRi-Associated Rash
➖ NeutralBenzinga•Aug 27, 2025, 12:11 PM
Azitra shares are trading higher after the company announced it has executed a 1-for-6.66 reverse stock split.
➖ NeutralBenzinga•Aug 22, 2025, 01:00 PM
Azitra shares are trading higher after the company announced it has executed a 1-for-6.66 reverse stock split.
➖ NeutralBenzinga•Aug 21, 2025, 08:09 PM
Azitra Executes 1-For-6.66 Reverse Stock Split Effective Aug. 21; Common Shares To Trade On Adjusted Basis Following Shareholder-Approved Amendment
➖ NeutralBenzinga•Aug 20, 2025, 08:40 PM
Frequently Asked Questions about AZTR
What is AZTR's current stock price?
Azitra, Inc. (AZTR) is currently trading at $0.29 per share. The stock has moved +3.19% today.
What is the analyst price target for AZTR?
No analyst price targets are currently available for this stock.
What sector is Azitra, Inc. in?
Azitra, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the AMEX exchange.
What is AZTR's market cap?
Azitra, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does AZTR pay dividends?
No, Azitra, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorENVB
Enveric Biosciences, Inc.
$5.08
Mkt Cap: $0.0B
INDP
Indaptus Therapeutics, Inc.
$2.03
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
LIPO
Lipella Pharmaceuticals Inc.
$0.21
Mkt Cap: $0.0B
ONCO
Onconetix, Inc.
$1.77
Mkt Cap: $0.0B
REVB
Revelation Biosciences, Inc.
$0.89
Mkt Cap: $0.0B
SCNI
Scinai Immunotherapeutics Ltd.
$0.79
Mkt Cap: $0.0B
SLRX
Salarius Pharmaceuticals, Inc.
$0.69
Mkt Cap: $0.0B
SLXN
Silexion Therapeutics Ltd.
$2.40
Mkt Cap: $0.0B
SPRC
SciSparc Ltd.
$1.46
Mkt Cap: $0.0B
Explore stocks similar to AZTR for comparison